Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Return on Sales (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Return on Sales for 8 consecutive years, with 32.21% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales fell 6108.0% to 32.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 32.21%, a 6108.0% decrease, with the full-year FY2025 number at 45.26%, down 6914.0% from a year prior.
  • Return on Sales was 32.21% for Q4 2025 at Outlook Therapeutics, up from 37.6% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 36.31% in Q1 2025 to a low of 37.6% in Q3 2025.